1Dameshek W. Some speculations on the myeloproliferative syn dromes. Blood, 1951,6 : 372.
2Johansson P. Epidemiology of the myeloproliferative disorders polycythemia vera and essential thromboeythemia. Semin Thromb Hemost, 2006,32:171.
3James C, Ugo V, Le Couedic JP, et al. A unique clonal JAK2 mutation leading to constitutive signaling causes polyeythemia vera. Nature,2005,434:1144.
4Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med, 2006,355 - 2452.
5James C. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases? Hematology, Am Soc Hematol Educ Program, 2008,2008: 69.
6Spivac JL, Silver RT. The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. Blood, 2008,112:231.
7Vardiman JW, Brunning RD, Arber DA, et al. Introduction and overview of the classification of the mteloid neoplasms. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edition. 2008. 23.
2Harrison C.Pregnancy and its management in the Philadelphia negative myeloproliferative diseases.Br J Haematol,2005,129:293 -306.
3Griesshammer M,Struve S,Barbui T.Management of Philadelphia negative chronic myeloproliferative disorders in pregnancy.Blood Reviews,2008,22:235 -245.
4Nelson SM,Greer IA.Thrombophilia and the risk for venous thromboembolism during pregnancy,delivery,and puerperium.Obstet Gynecol Clin North Am,2006,33:413-427.
5Gotic M,Cvetkovic M,Bozanovic T,et al.Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon.Srp Arh Celok Lek,2001,129:304-308.
6Landolfi R,Rocca B,Patrono C.Bleeding and thrombosis in myeloproliferative disorders:mechanisms and treatment.Crit Rev Oncol Hematol,1995,20:203-222.
8Levine RL, Wemig G. Role of JAK-STAT signaling in the pathogenesis of myeloproliferative disorders. Hematology Am Soc Hematol Educ Program, 2006, : 233-239,510.
9Thomas GP, Elsea C, Corbin AS, et al. Characterization of murine JAK2V617F positive myeloproliferative disease. Cancer Res, 2006,66(23) :11156-11165.
10Tefferi A, Varidiman JW myeloproliferative neoplasms Classification the 2008 and diagnosis of World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia , 2008, 22(1): 14 -22.
